EVH (Evolent Health) 3-Year RORE % : 48.48% (As of Mar. 2026)


EVH Evolent Health Inc EVH
65 GF Score
Price $5.80
GF Value $11.20
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Evolent Health 3-Year RORE %?

Evolent Health EVH +1.49% 65 3-Year RORE % is 48.48 as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 65/100 and a GF Value™ of $11.20 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Evolent Health ranks better than 82.98% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Evolent Health's 3-Year RORE % for the quarter that ended in Mar. 2026 was 48.48%.

The industry rank for Evolent Health's 3-Year RORE % or its related term are showing as below:

EVH's 3-Year RORE % is ranked better than
82.98% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: -0.32 vs EVH: 48.48

Evolent Health  (NYSE:EVH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Evolent Health 3-Year RORE % Related Terms


Evolent Health 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Evolent Health's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health 3-Year RORE % Chart

Evolent Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.92 -81.58 43.46 27.07 53.59

Evolent Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.72 28.00 15.95 53.59 48.48

EVH vs PHR, CTEV, MDRX: 3-Year RORE % Comparison

For the Health Information Services subindustry, Evolent Health's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Evolent Health's 3-Year RORE % falls into.


EVH
65GF Score
Evolent Health Inc EVH
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolent Health 3-Year RORE % Calculation

Evolent Health's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -4.76--1.25 )/( -7.24-0 )
=-3.51/-7.24
=48.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 48.48 mean?
Evolent Health (EVH) has a 3-Year RORE % of 48.48 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #103 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 17%.
Is Evolent Health's 3-Year RORE % too high?
Evolent Health's current 3-Year RORE % is 48.48. Based on the distribution chart, Evolent Health ranks #103 out of 605 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Evolent Health has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's 3-Year RORE % compare to PHR and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #103 out of 605 companies for 3-Year RORE %. This places Evolent Health in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
A good 3-Year RORE % depends on the Healthcare Providers & Services industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Evolent Health and its competitors. Evolent Health's current 3-Year RORE % is 48.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.20, compared to a current price of $5.80 — trading 48.3% below its estimated fair value. The current 3-Year RORE % is 48.48. Evolent Health's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Evolent Health (EVH), the current 3-Year RORE % is 48.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (EVH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of $5.80 is trading 48.3% below its estimated GF Value™ of $11.20. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for EVH:

  • 3-Year RORE %: 48.48
  • GF Value™: $11.20 vs. price of $5.80 (48.3% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolent Health Business Description

Other Exchanges 9EH:Germany
Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
65GF Score

Get the complete analysis for EVH

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.80
Price
$11.20
GF Value